Uric Acid, the End-Product of Purine Metabolism, Mitigates Tau-Related Abnormalities: Comparison with DOT, a Non-Antibiotic Oxytetracycline Derivative
; Alves Fernandes, Thaís Antonia ; González Lizárraga, Florencia ; Tourville, Aurore ; Ciss, Ismaila ; Brunel, Jean Michel ; Chehin, Rosana Nieves
; Lannuzel, Annie ; Ferrié, Laurent ; Raisman Vozari, Rita ; Figadère, Bruno ; Del Bel, Elaine ; Michel, Patrick Pierre Otros responsables
Fecha
06/2025
Editorial
MDPI
Revista
Biomolecules
Título del libro
Nombre del evento
Fecha del evento
Institución organizadora
ISSN
2218-273X
eISSN
ISBN
Idioma
Inglés
Tipo del evento
Clasificación temática
Palabras clave
Resumen
We aimed to simulate tau abnormalities—specifically hyperphosphorylation and aggregation—that are hallmarks of tauopathies, including Alzheimer’s disease, to evaluate tau-targetingtherapies. Tomodel pathological p-tau accumulation at early disease stages, we exposedmousecortical cultures to redox-active iron fromhemin (Hm), a breakdown product of hemoglobin, orchallenged themwith the excitatory neurotransmitter glutamate. Using theAT8 phospho-specificantibody, we demonstrate that a subtoxic concentration of Hm (3 M) promotes pathologicalp-tau accumulation in a subpopulation of cultured cortical neurons and their proximal neurites.Uric acid (UA; 0.1–200 M), themetabolic end-product of purines in humans, prevented p-taubuild-up. Neither xanthine, the immediate precursor of UA, nor allantoin, its oxidized product,reproduced this effect. Live cell imaging studies revealed that UA operates by repressing irondrivenlipid peroxidation. DOT (3 M), a brain-permeant tetracycline (TC) without antibioticactivity, mimicked UA’s anti-tau and antioxidant effects. Interestingly, both UA and DOTremained effective in preventing p-tau accumulation induced by glutamate (10 M). To simulatetau aggregation at more advanced disease stages, we conducted a Thioflavin-T aggregationassay. Our findings revealed that UA and DOT prevented tau aggregation seeded by heparin.However, only DOT remained effective when heparin-assembled tau fibrils were used as theseedingmaterial. In summary, our results indicate thatUA-elevating agentsmay hold therapeuticutility for tauopathies. The non-purine compound DOT could serve as an effective alternative toUA-related therapies.
Colecciones
Aprobación
Revisión
Complementado por
Referenciado por
Licencia Creative Commons
Excepto donde se indique lo contrario, la licencia de este ítem se describe como by
